Oral vitamin K (phytonadione and menaquinone-4) is associated with increased bone mineral density and reduced fracture incidence of up to 80% for hip fractures, according to a meta-analysis. Pooling the results of seven trials with fracture outcomes, researchers calculated an odds ratio favoring menaquinone of 0.40 (95% CI; 0.25–0.65) for vertebral fractures, 0.23 (95% CI; 0.12–0.47) for hip fractures, and 0.19 (95% CI; 0.11–0.35) for all nonvertebral fractures.
Oral vitamin K (phytonadione and menaquinone-4) is associated with increased bone mineral density and reduced fracture incidence of up to 80% for hip fractures, according to a meta-analysis. Pooling the results of seven trials with fracture outcomes, researchers calculated an odds ratio favoring menaquinone of 0.40 (95% CI; 0.25–0.65) for vertebral fractures, 0.23 (95% CI; 0.12–0.47) for hip fractures, and 0.19 (95% CI; 0.11–0.35) for all nonvertebral fractures.
But the authors of the review caution that the included studies were not designed to show a fracture effect, and such a dramatic effect-much larger than with treatments such as bisphosphonates-could be due to chance, the fact that all the studies with fracture outcomes were performed in Japan, and may be explained by some dietary or other lifestyle factor, or to some other unidentified factor.
Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1256-1261.
Disparities in kidney care access for pregnant patients
December 11th 2023A recent study highlights significant disparities in kidney transplant and nephrology care access for pregnant patients with end-stage kidney disease, revealing reduced survival rates and limited access to crucial care compared to non-pregnancy-related causes.
Read More
Mediterranean diet linked to improved pregnancy outcomes
December 8th 2023A comprehensive meta-analysis scrutinizes the Mediterranean diet's impact on female reproductive health, uncovering compelling evidence that links this nutritional approach to a significant reduction in adverse pregnancy outcomes.
Read More
FDA grants IND clearance to DARE-VVA1 for dyspareunia
December 7th 2023Daré Bioscience's tamoxifen-based therapy, DARE-VVA1, secures FDA clearance for an investigational new drug application, offering hope for women with contraindications to estrogen therapies suffering from the underdiagnosed condition of vulvar and vaginal atrophy.
Read More